MKI67 and neoplasm: Compared with cisplatin or PBS groups, the percentage of Ki67-positive tumor cells in the Ad-TD-nsIL12 group was significantly decreased at all timepoints (p < 0.05) (Figure 6A), demonstrating that Ad-TD-nsIL12 could effectively inhibit the proliferation of tumor cells.